You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
|
|---|---|
| Published in |
Journal of Antimicrobial Chemotherapy (JAC), October 2015
|
| DOI | 10.1093/jac/dkv288 |
| Pubmed ID | |
| Authors |
Mohd H. Abdul-Aziz, Jeffrey Lipman, Murat Akova, Matteo Bassetti, Jan J. De Waele, George Dimopoulos, Joel Dulhunty, Kirsi-Maija Kaukonen, Despoina Koulenti, Claude Martin, Philippe Montravers, Jordi Rello, Andrew Rhodes, Therese Starr, Steven C. Wallis, Jason A. Roberts, on behalf of the DALI Study Group, Jason A. Roberts, Jeffrey Lipman, Therese Starr, Steven C. Wallis, Sanjoy Paul, Antonio Margarit Ribas, Jan J. De Waele, Luc De Crop, Herbert Spapen, Joost Wauters, Thierry Dugernier, Philippe Jorens, Ilse Dapper, Daniel De Backer, Fabio S. Taccone, Jordi Rello, Laura Ruano, Elsa Afonso, Francisco Alvarez-Lerma, Maria Pilar Gracia-Arnillas, Francisco Fernández, Neus Feijoo, Neus Bardolet, Assumpta Rovira, Pau Garro, Diana Colon, Carlos Castillo, Juan Fernado, Maria Jesus Lopez, Jose Luis Fernandez, Ana Maria Arribas, Jose Luis Teja, Elsa Ots, Juan Carlos Montejo, Mercedes Catalan, Isidro Prieto, Gloria Gonzalo, Beatriz Galvan, Miguel Angel Blasco, Estibaliz Meyer, Frutos Del Nogal, Loreto Vidaur, Rosa Sebastian, Pila Marco Garde, Maria del Mar Martin Velasco, Rafael Zaragoza Crespo, Mariano Esperatti, Antoni Torres, Philippe Montravers, Olivier Baldesi, Herve Dupont, Yazine Mahjoub, Sigismond Lasocki, Jean Michel Constantin, Jean François Payen, Claude Martin, Jacques Albanese, Yannick Malledant, Julien Pottecher, Jean-Yves Lefrant, Samir Jaber, Olivier Joannes-Boyau, Christophe Orban, Marlies Ostermann, Catherine McKenzie, Willaim Berry, John Smith, Katie Lei, Francesca Rubulotta, Anthony Gordon, Stephen Brett, Martin Stotz, Maie Templeton, Andrew Rhodes, Claudia Ebm, Carl Moran, Kirsi-Maija Kaukonen, Ville Pettilä, George Dimopoulos, Despoina Koulenti, Aglaia Xristodoulou, Vassiliki Theodorou, Georgios Kouliatsis, Eleni Sertaridou, Georgios Anthopoulos, George Choutas, Thanos Rantis, Stylianos Karatzas, Margarita Balla, Metaxia Papanikolaou, Pavlos Myrianthefs, Alexandra Gavala, Georgios Fildisis, Antonia Koutsoukou, Magdalini Kyriakopoulou, Kalomoira Petrochilou, Maria Kompoti, Martha Michalia, Fillis-Maria Clouva-Molyvdas, Georgios Gkiokas, Fotios Nikolakopoulos, Vasiliki Psychogiou, Polychronis Malliotakis, Evangelia Akoumianaki, Emmanouil Lilitsis, Vassilios Koulouras, George Nakos, Mihalis Kalogirou, Apostolos Komnos, Tilemachos Zafeiridis, Christos Chaintoutis, Kostoula Arvaniti, Dimitrios Matamis, Christos Chaintoutis, Christina Kydona, Nikoleta Gritsi-Gerogianni, Tatiana Giasnetsova, Maria Giannakou, Ioanna Soultati, Ilias Chytas, Eleni Antoniadou, Elli Antipa, Dimitrios Lathyris, Triantafyllia Koukoubani, Theoniki Paraforou, Kyriaki Spiropoulou, Vasileios Bekos, Anna Spring, Theodora Kalatzi, Hara Nikolaou, Maria Laskou, Ioannis Strouvalis, Stavros Aloizos, Spyridon Kapogiannis, Ourania Soldatou, Matteo Bassetti, Chiara Adembri, Gianluca Villa, Antonio Giarratano, Santi Maurizio Raineri, Andrea Cortegiani, Francesca Montalto, Maria Teresa Strano, V. Marco Ranieri, Claudio Sandroni, Gennaro De Pascale, Alexandre Molin, Paolo Pelosi, Luca Montagnani, Rosario Urbino, Ilaria Mastromauro, Francesco G. De Rosa, V. Marco Ranieri, Teresa Cardoso, Susana Afonso, João Gonçalves-Pereira, João Pedro Baptista, Murat Akova, Arife Özveren |
| Abstract |
We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged-infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DALI study, 182 met inclusion criteria. Overall, 89.0% (162/182) of patients achieved the most conservative target of 50% fT>MIC (time over which unbound or free drug concentration remains above the MIC). Decreasing creatinine clearance and the use of prolonged infusion significantly increased the PTA for most pharmacokinetic/pharmacodynamic targets. In the subgroup of patients who had respiratory infection, patients receiving β-lactams via prolonged infusion demonstrated significantly better 30 day survival when compared with intermittent-bolus patients [86.2% (25/29) versus 56.7% (17/30); P = 0.012]. Additionally, in patients with a SOFA score of ≥9, administration by prolonged infusion compared with intermittent-bolus dosing demonstrated significantly better clinical cure [73.3% (11/15) versus 35.0% (7/20); P = 0.035] and survival rates [73.3% (11/15) versus 25.0% (5/20); P = 0.025]. Analysis of this large dataset has provided additional data on the niche benefits of administration of piperacillin/tazobactam and meropenem by prolonged infusion in critically ill patients, particularly for patients with respiratory infections. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 35% |
| United States | 3 | 18% |
| India | 1 | 6% |
| Korea, Democratic People's Republic of | 1 | 6% |
| Myanmar | 1 | 6% |
| Unknown | 5 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 59% |
| Practitioners (doctors, other healthcare professionals) | 4 | 24% |
| Scientists | 3 | 18% |
Mendeley readers
The data shown below were compiled from readership statistics for 187 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | <1% |
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 184 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 23 | 12% |
| Researcher | 23 | 12% |
| Student > Ph. D. Student | 18 | 10% |
| Student > Doctoral Student | 14 | 7% |
| Professor | 14 | 7% |
| Other | 40 | 21% |
| Unknown | 55 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 71 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 29 | 16% |
| Agricultural and Biological Sciences | 6 | 3% |
| Immunology and Microbiology | 3 | 2% |
| Biochemistry, Genetics and Molecular Biology | 2 | 1% |
| Other | 7 | 4% |
| Unknown | 69 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2022.
All research outputs
#3,059,938
of 25,394,764 outputs
Outputs from Journal of Antimicrobial Chemotherapy (JAC)
#1,173
of 8,177 outputs
Outputs of similar age
#40,133
of 289,013 outputs
Outputs of similar age from Journal of Antimicrobial Chemotherapy (JAC)
#17
of 117 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,177 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,013 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.